Unknown Analyst

So thank you for joining us again this afternoon at the Life Sciences — Citizens Life Sciences Conference. Excited to be joined next by Axsome. I’m going to turn it over to Mark Jacobson, the Chief Operating Officer, and we’re also joined by CFO, Nick Pizzie. Thank you.

Mark Jacobson
Chief Operating Officer

Yes. Thanks very much, Jason, and thanks to the Citizens team for having us. And we’ll do this in 2 parts. So Nick and I will run through a brief overview of the company, and then we’ll open it up for Q&A. So thanks again for having us.

And very quickly, of course, we’ve got obligatory forward-looking statements, and we may be making forward-looking statements today. So please review our filings with the Securities and Exchange Commission for a complete summary and overview of the risks and uncertainties associated with our business. Axsome is a commercial and clinical stage biopharmaceutical company. We are focused on central nervous system disorders, in particular, frontiers in central nervous system disorders, and our mission is to develop and deliver transformative medicines for the hundreds of millions of people impacted by CNS conditions.

2025 highlights, Nick, you want to cover those questions?

Nick Pizzie
Chief Financial Officer

Sure. Yes. 2025 was a successful year for Axsome. We — a couple of milestones that we hit for the year from a sales perspective was Auvelity surpassed over $0.5 billion in revenue. That was only the third year since launch. And total sales for the company were close to $640 million. So super excited. It’s a nice setup for 2026 and how we’re approaching on — and the success that we’ve had in 2025. The